NASDAQ:ITOS iTeos Therapeutics (ITOS) Stock Price, News & Analysis $8.22 -0.13 (-1.56%) Closing price 04:00 PM EasternExtended Trading$8.40 +0.18 (+2.18%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About iTeos Therapeutics Stock (NASDAQ:ITOS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get iTeos Therapeutics alerts:Sign Up Key Stats Today's Range$8.12▼$8.4450-Day Range$5.04▼$8.4152-Week Range$4.80▼$18.30Volume1.97 million shsAverage Volume561,932 shsMarket Capitalization$314.61 millionP/E RatioN/ADividend YieldN/APrice Target$17.86Consensus RatingHold Company OverviewiTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.Read More… iTeos Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreITOS MarketRank™: iTeos Therapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 402nd out of 915 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingiTeos Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 3 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageiTeos Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about iTeos Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for iTeos Therapeutics are expected to decrease in the coming year, from ($3.49) to ($4.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of iTeos Therapeutics is -2.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of iTeos Therapeutics is -2.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioiTeos Therapeutics has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.64% of the float of iTeos Therapeutics has been sold short.Short Interest Ratio / Days to CoveriTeos Therapeutics has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in iTeos Therapeutics has recently increased by 25.25%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldiTeos Therapeutics does not currently pay a dividend.Dividend GrowthiTeos Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.64% of the float of iTeos Therapeutics has been sold short.Short Interest Ratio / Days to CoveriTeos Therapeutics has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in iTeos Therapeutics has recently increased by 25.25%, indicating that investor sentiment is decreasing significantly. News and Social Media2.5 / 5News Sentiment0.45 News SentimentiTeos Therapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 30 news articles for iTeos Therapeutics this week, compared to 3 articles on an average week.Search Interest7 people have searched for ITOS on MarketBeat in the last 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, iTeos Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,396,703.00 in company stock.Percentage Held by Insiders12.50% of the stock of iTeos Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.16% of the stock of iTeos Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about iTeos Therapeutics' insider trading history. Receive ITOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iTeos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ITOS Stock News HeadlinesiTeos Therapeutics, Inc. (NASDAQ:ITOS) Major Shareholder Bioventures 2018 L.P. Mpm Sells 630,191 SharesMay 16, 2025 | insidertrades.comWhat is Leerink Partnrs' Estimate for ITOS Q2 Earnings?May 20 at 1:35 AM | americanbankingnews.comWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."May 21, 2025 | Brownstone Research (Ad)iTeos Therapeutics (NASDAQ:ITOS) Rating Lowered to Hold at Leerink PartnrsMay 17, 2025 | americanbankingnews.comResearch Analysts Issue Forecasts for ITOS Q2 EarningsMay 17, 2025 | americanbankingnews.comLeerink Partners Reaffirms "Market Perform" Rating for iTeos Therapeutics (NASDAQ:ITOS)May 17, 2025 | americanbankingnews.comReviewing iTeos Therapeutics (NASDAQ:ITOS) & CG Oncology (NASDAQ:CGON)May 17, 2025 | americanbankingnews.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) Receives $18.83 Average Price Target from AnalystsMay 17, 2025 | americanbankingnews.comSee More Headlines ITOS Stock Analysis - Frequently Asked Questions How have ITOS shares performed this year? iTeos Therapeutics' stock was trading at $7.68 on January 1st, 2025. Since then, ITOS stock has increased by 7.0% and is now trading at $8.22. View the best growth stocks for 2025 here. How were iTeos Therapeutics' earnings last quarter? iTeos Therapeutics, Inc. (NASDAQ:ITOS) posted its earnings results on Monday, April, 28th. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($0.94) by $0.14. When did iTeos Therapeutics IPO? iTeos Therapeutics (ITOS) raised $151 million in an IPO on Friday, July 24th 2020. The company issued 8,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, SVB Leerink and Piper Sandler served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are iTeos Therapeutics' major shareholders? Top institutional investors of iTeos Therapeutics include RA Capital Management L.P. (9.53%), BVF Inc. IL (8.03%), 683 Capital Management LLC (4.57%) and Goldman Sachs Group Inc. (1.53%). Insiders that own company stock include Ansbert Gadicke, Bioventures 2018 LP Mpm, Boxer Capital, Llc, Matthew Gall and David Hallal. View institutional ownership trends. How do I buy shares of iTeos Therapeutics? Shares of ITOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of iTeos Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that iTeos Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Tesla (TSLA) and Palo Alto Networks (PANW). Company Calendar Last Earnings4/28/2025Today5/21/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ITOS CIK1808865 Webwww.iteostherapeutics.com Phone339-217-0161FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Stock Price Target$17.86 High Stock Price Target$46.00 Low Stock Price Target$8.00 Potential Upside/Downside+117.2%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-112,640,000.00 Net MarginsN/A Pretax Margin-320.49% Return on Equity-20.11% Return on Assets-17.50% Debt Debt-to-Equity RatioN/A Current Ratio14.80 Quick Ratio14.80 Sales & Book Value Annual Sales$35 million Price / Sales8.99 Cash FlowN/A Price / Cash FlowN/A Book Value$16.08 per share Price / Book0.51Miscellaneous Outstanding Shares38,274,000Free Float31,967,000Market Cap$314.61 million OptionableOptionable Beta1.39 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:ITOS) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iTeos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iTeos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.